Dermatology Times Spot Test：与Charrow医生共同聚焦毛囊闭锁三联征管理

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Welcome to Dermatology Times' Spot Test!

Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on hidradenitis suppurativa (HS) management, including biologic treatment, deroofing, and emerging strategies discussed by Alexandra Charrow, MD, FAAD, at Maui Derm NP+PA Fall 2026.

Do you have a set of quiz questions to share? Contact editor Shannon Heaning at Sheaning@mjhlifesciences.com to contribute.

According to Alexandra Charrow, MD, FAAD, which clinical findings can help clinicians assess the inflammatory burden of hidradenitis suppurativa when considering escalation to biologic therapy?

What procedural intervention did Charrow encourage dermatology clinicians to become more comfortable incorporating into hidradenitis suppurativa care?

What emerging area of research did Charrow identify as potentially helping clinicians select the most appropriate hidradenitis suppurativa therapy for individual patients?

Related to this article